Researchers said the previous results on high sensitivity C-reactive protein and migraine are mixed, and the relationship to insomnia limited; the aim of this study was to evaluate the cross-sectional association between hs-CRP and types of headache, and to see whether the relationship to insomnia could be reproduced.
The study was largely funded the National Institutes of Health, and results appeared in the Journal of the American Heart Association.
As practices work to provide the best care for their patients while also containing costs, it has become clear that the old ways of doing things won’t cut it.
Ozanimod, under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Medicare cut payments to 2583 hospitals for penalties related to 30-day patient readmissions; a judge delivers a mixed ruling on Virginia abortion law; a study finds vitamin A is linked to a lower risk of squamous cell carcinoma.
Pirfenidone was shown to potentially benefit patients with uILD in a phase 2 trial, according to research presented at the European Respiratory Society Congress 2019 in Madrid, Spain.
The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic kidney disease.
According to results of a survey asking 1300 Americans about their perceptions and knowledge of sleep disorders like narcolepsy, many respondents were not familiar with common symptoms of the disease and their understanding was often shaped by television shows or movies.
Knowing who may respond to tildrakizumab early on may help providers and patients decide whether to continue with treatment, the researchers said.
Here are 5 interesting findings from the September 2019 issue of AJMC®.
Here are the top 5 articles for the month of September.
EpiPen manufacturer settles $30 million claim; THC-containing brands cited as potential cause of vaping epidemic; Idaho submits work-requirement waiver for Medicaid expansion.
Since healthcare benefit costs continue to rise, large employers are increasing efforts to stem the increases, according to the annual survey by the National Business Group on Health.
According to the findings, adding poly (ADP ribose) polymerase (PARP) inhibitor olaparib to bevacizumab extended progression-free survival (PFS) in women with advanced stage ovarian cancer, with or without a BRCA mutation.
Cognitive status may be affected by the relationship of Parkinson disease (PD) and affective theory of mind through the involvement of visuospatial abilities (VSA), a recent study reported.
A recent study investigating the cardiovascular contribution to COPD symptoms and their relationship to a patient's diagnostic status found that patients with suspicious echocardiographic findings were undiagnosed and untreated.
The new indication is the seventh overall for the therapy, according to Janssen.
An immunoglobulin G (IgG) elimination diet combined with probiotics may be effective and beneficial for patients with both migraine and irritable bowel syndrome (IBS), according to a recent study,
Adherence to documenting asthma severity or control and providing ample education to patients was low among physicians from 2012-2015, with primary care providers monitoring nearly two-thirds of asthma-related visits, according to a federal report.
During a panel discussion on defining, standardizing, and reporting quality in cancer care during the National Comprehensive Cancer Network Policy Summit held September 12 in Washington, DC, it became clear that stakeholders of all backgrounds have set their focus on one type of metric in particular: patient-reported outcomes.
This week, the top managed care news included state and federal crackdowns on vaping that forced out the president of Juul; FDA approved a groundbreaking diabetes treatment; Medicare Advantage premiums will decline for 2020.
Data on the link between elevated serum neurofilament light chain and diabetes was presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, held in Stockholm, Sweden.
Older adults above the age of 66 with COPD were found to be twice as likely to use prescription synthetic oral cannabinoids when compared with adults of the same age without COPD, according to a study.
The CDC reports a 52% rise in vaping-related illnesses from last week; bundled payment models are being tried for maternity care costs; the chief executive officer of Blue Cross and Blue Shield of North Carolina has resigned and a merger put on hold after news of his alleged alcohol-related crash 3 months ago became public.
According to the researchers, the long noncoding RNA, when turned off or deleted, eliminates dormant HIV reservoirs that persist even when patients adhere here to their antiretroviral therapy regimen and are virally suppressed.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Researchers studied a particular mutation in a gene linked to Parkinson.
Coverage of the first half of the Institute for Value-Based Medicine® (IVBM®) session held September 19, 2019, in Philadelphia, Pennsylvania. IVBM® is an initiative of The American Journal of Managed Care®.
Boston Scientific announced its fifth annual Connected Patient Challenge, a campaign seeking digital health solutions that improve patient care and better manage chronic conditions
Patients with psoriasis who were treated with biologics were less likely to develop psychiatric illnesses compared with patients not treated with biologics; however, the researchers did note treatment selection may have influenced the findings.